Follow us on:

Tissue Regenix well positioned to forge ahead with its strategic goals (Analyst Interview)

Tissue Regenix plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains what the company does, what has been happening at the company, turning a corner, risks and Martins view on the company as an investment case.

Tissue Regenix is an international medical device company focused on the development and commercialisation of products for regenerative medicine. It has two proprietary platform technologies, dCELL and BioRinse, from which all its products are derived, dCELL being an in-house development and BioRinse acquired with the CellRight acquisition in 2018.

You might also enjoy reading Surface Transforms Plc: Strategic Moves and Market Potential with Mike Foster

Find more news, interviews, share price & company profile here for:

Hardman & Co

Share this interview

Other Interviews

Real Estate Credit Investments, Insights from Hardman & Co Analyst Mike Foster on Strategy and Resilience (VIDEO) August 5, 2024
Duke Capital Record cashflows in FY’24 (Video) July 24, 2024
Apax Global Alpha CM Day Presentation – How Apax adds Value (VIDEO) July 23, 2024
ICG Enterprise Trust Capital Market Day: Value added by defensive growth strategy (VIDEO) July 11, 2024
Accesso Technology Group: Leading the Way in Leisure Industry Solutions (VIDEO) June 28, 2024
Volta Finance The discount in absolute and relative perspectives (VIDEO) June 18, 2024
ICG Enterprise Trust Portfolio companies growing earnings and widening margins (VIDEO) May 28, 2024
NB Private Equity Partners Robust Growth and Widening EBITDA Margins (VIDEO) May 23, 2024
Duke Capital Generating investor returns by uniquely meeting customer needs (VIDEO) May 17, 2024
Chesnara plc Growth and Stability Insights with Dr. Brian Moretta (VIDEO) May 9, 2024

More News

Asia market dynamics gives favourable tailwinds to Fidelity Asian Values investment trust (LON: FAS) (VIDEO) July 22, 2022
Volta Finance huge diverse portfolio with good long-term cashflows (Analyst VIDEO) July 15, 2022
Fidelity European Trust – Key strengths to weather headwinds (Analyst VIDEO) April 29, 2022
Asia investment opportunity: FAS trust success in disciplined Fidelity approach April 19, 2022
CyanConnode revenue opportunity hundreds of millions (Analyst Interview) February 21, 2022
Volta Finance: What Volta brings to investors February 18, 2022
Volta Finance: Re-Set, Re-Fi, Re-Light my Fire May 5, 2021
Tissue Regenix Restructured to satisfy product demand February 6, 2020
How can FTSE and AIM companies engage with a wider audience? (Interview) January 21, 2020
ANALYST INTERVIEW: PANTHEON INTERNATIONAL PLC 11.9% average annual NAV growth since 1987 September 18, 2019

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.